Brooks Laboratories Limited

BROOKS.NS

BROOKS.NSBrooks Laboratories Limited IN flag

National Stock Exchange of India

101.78

INR

-1.23

(-1.19%)

-6.99EPS

-14.56P/E

2.67BMarket Cap

May 16Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

INE650L01011

CUSIP

Y0975G108

Return %

Stock

S&P500

-2.40

18.57

45.68

40.07

387.78

86.07

Use logarithmic scale

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	28.61	40.87	43.5	43.47	40.82	29.35	28.42	27.38	38.88	30.88	35.77	25.29	30.84	30.04
Basic EPS, GAAP	4.51	3.64	3.69	4.83	5.42	0.85	-7.05	-7.37	-13.71	-7.77	-7.67	-8.46	-7.65	-7.68
Free Cash Flow per Basic Share	-12.14	1.72	4.42	-9.12	-14.18	-4.11	-6.08	-2.94	-6.73	-0.46	-24.08	-6.06	-3.95	- -
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Book Value per Share	17.37	24.59	28.36	29.59	37.29	38.14	31.09	22.96	17	4.35	0.43	2.27	-4.86	10.15
Tangible Book Value per Share	46.56	53.77	57.29	56.84	64.54	65.44	58.4	52.13	55.18	31.45	53.08	29.86	25.57	22.88
Basic Weighted Avg Shares	20	20	20	20	20	20	20	20	18	25	25	25	26	26
Sales/Revenue/Turnover	561	801	853	852	800	575	557	550	691	770	901	625	790	777
Operating Margin (%)	17.52	12.1	9.02	7.22	12.79	5.86	-27.59	-22	-13.37	-8.57	-24.09	-53.7	1.83	1.99
Depreciation Expense	7	8	8	11	12	17	64	65	66	71	74	70	18	17
Net Income, GAAP	88	71	72	95	106	17	-138	-148	-244	-194	-193	-209	-196	-199
Effective Tax Rate (%)	3.64	25.45	4.38	8.53	1.71	32.86	- -	- -	- -	- -	- -	- -	- -	- -
Profit Margin (%)	15.76	8.92	8.49	11.11	13.29	2.9	-24.79	-26.9	-35.26	-25.15	-21.44	-33.44	-24.8	-25.56
Working Capital	278	416	367	326	16	-24	-98	-157	-79	-163	123	-54	80	92
LT Debt	- -	- -	- -	- -	3	107	166	139	119	144	101	6	4	17
Total Equity	913	1,054	1,123	1,114	1,265	1,283	1,145	1,052	984	791	1,343	740	656	592
Return on Invested Capital (%)	15.73	7.27	6.72	5	8.22	1.65	- -	- -	- -	- -	- -	- -	- -	- -
Return on Capital (%)	28.22	16.94	13.94	16.91	16.56	2.7	- -	- -	- -	- -	- -	- -	- -	- -
Return on Common Equity (%)	33.36	17.37	13.95	16.67	16.22	2.25	-20.36	-27.65	-63.83	-94.32	-323.52	-624.12	-123.03	-75.67

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	1.12%	9.96%	26.46%
Net Income, GAAP	-91.69%	9.15%	-6.22%
Free Cash Flow	473.17%	1,011.21%	-32.35%
Total Cash Common Dividend	- -	- -	- -
Total Equity	-1.73%	-2.51%	-11.32%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Mr. Prashant Rathi
Full Time Employees: 293
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Address: 201, The Summit Business Park Mumbai India 400093
IPO Date: Sep 5, 2011
Website: brookslabs.net
Similar Companies: SNDL Inc. (SNDL)
Redwood Scientific Technologies, Inc. (RSCI)
Shandong Buchang Pharmaceuticals Co., Ltd. (603858.SS)
ChengDu ShengNuo Biotec Co.,Ltd. (688117.SS)
Albert David Limited (ALBERTDAVD.NS)
Orexo AB (publ) (ORXOF)
Business: Brooks Laboratories Limited manufactures and sells pharmaceuticals on contract basis in India and internationally. It offers carbapenem drugs; tablets; dry syrup; liquid and dry power injections; and eye and ear drop. Brooks Laboratories Limited was incorporated in 2002 and is based in Mumbai, India.

	2012 Y	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	2024 Y	TTM
Revenue per Share	28.61	40.87	43.5	43.47	40.82	29.35	28.42	27.38	38.88	30.88	35.77	25.29	30.84	30.04
Basic EPS, GAAP	4.51	3.64	3.69	4.83	5.42	0.85	-7.05	-7.37	-13.71	-7.77	-7.67	-8.46	-7.65	-7.68
Free Cash Flow per Basic Share	-12.14	1.72	4.42	-9.12	-14.18	-4.11	-6.08	-2.94	-6.73	-0.46	-24.08	-6.06	-3.95	- -
Dividend per Share	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -	- -
Book Value per Share	17.37	24.59	28.36	29.59	37.29	38.14	31.09	22.96	17	4.35	0.43	2.27	-4.86	10.15
Tangible Book Value per Share	46.56	53.77	57.29	56.84	64.54	65.44	58.4	52.13	55.18	31.45	53.08	29.86	25.57	22.88
Basic Weighted Avg Shares	20	20	20	20	20	20	20	20	18	25	25	25	26	26
Sales/Revenue/Turnover	561	801	853	852	800	575	557	550	691	770	901	625	790	777
Operating Margin (%)	17.52	12.1	9.02	7.22	12.79	5.86	-27.59	-22	-13.37	-8.57	-24.09	-53.7	1.83	1.99
Depreciation Expense	7	8	8	11	12	17	64	65	66	71	74	70	18	17
Net Income, GAAP	88	71	72	95	106	17	-138	-148	-244	-194	-193	-209	-196	-199
Effective Tax Rate (%)	3.64	25.45	4.38	8.53	1.71	32.86	- -	- -	- -	- -	- -	- -	- -	- -
Profit Margin (%)	15.76	8.92	8.49	11.11	13.29	2.9	-24.79	-26.9	-35.26	-25.15	-21.44	-33.44	-24.8	-25.56
Working Capital	278	416	367	326	16	-24	-98	-157	-79	-163	123	-54	80	92
LT Debt	- -	- -	- -	- -	3	107	166	139	119	144	101	6	4	17
Total Equity	913	1,054	1,123	1,114	1,265	1,283	1,145	1,052	984	791	1,343	740	656	592
Return on Invested Capital (%)	15.73	7.27	6.72	5	8.22	1.65	- -	- -	- -	- -	- -	- -	- -	- -
Return on Capital (%)	28.22	16.94	13.94	16.91	16.56	2.7	- -	- -	- -	- -	- -	- -	- -	- -
Return on Common Equity (%)	33.36	17.37	13.95	16.67	16.22	2.25	-20.36	-27.65	-63.83	-94.32	-323.52	-624.12	-123.03	-75.67

Year	Q1	Q2	Q3	Q4	FY
2023	-2.77	-1.88	-2.03	- -	-8.46
2024	-1.81	-0.6	-1.51	- -	-7.65
2025	-0.94	-1.51	- -	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2023	171	181	153	120	625
2024	157	243	217	172	790
2025	179	208	- -	- -	- -

	Mar'24	Jun'25	Sep'25
ST Debt	53	- -	73
LT Borrowings	- -	- -	1
LT Finance Leases	4	- -	16
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	26	- -	26
Market Capitalization	2,423	2,274	3,893

	Mar'24	Jun'25	Sep'25
Total Current Assets	310	- -	379
Accounts Receivable, Net	163	- -	237
Cash, Cash Equivalents & STI	25	- -	24
Inventories	96	- -	95
Total Current Liabilities	230	- -	287
Payables & Accruals	- -	- -	- -
ST Debt	53	- -	73
Deferred Revenue	- -	- -	- -

Brooks Laboratories Limited

Growth Rates

(avg. rate of change)

Company Description

Growth Rates

(avg. rate of change)

Quarterly Earnings Per Share

Year

Capital Structure

Working Capital

Quarterly Revenue

Year

Quarterly Dividends Per Share

Year